• Home
  • CARBOGEN AMCIS

CARBOGEN AMCIS

About CARBOGEN AMCIS

CARBOGEN AMCIS leverages its world-class chemistry skills to provide seamless drug substance, drug products development and commercialization services for leading pharmaceutical and biopharmaceutical companies. We help customers create a better world by becoming the partner of choice thanks to our innovative solutions. We offer an array of integrated and customized services operating in a fully cGMP-compliant infrastructure, including dedicated Highly Potent API facilities and a clean room for Antibody Drug Conjugates.

Read more Show less
Certifications
  • GMP
    GMP
More certifications Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • CH
  • 2015
    On CPHI since
  • 1
    Certificates
  • 1000 - 4999
    Employees
Company types
CMO/CDMO
Contract Service
Primary activities
API Producer
Clinical Research
Contract Manufacturer
Contract Research Organisation
View company profile
Contact info
Show contact info Hide contact info
Meet us at

CPHI Japan 2025

East Halls 4, 5 & 6, Tokyo Big Sight, Tokyo, Japan
09 Apr 2025 – 11 Apr 2025
View Exhibitor Profile

CPHI Americas 2025

Pennsylvania Convention Center, Philadelphia
20 May 2025 - 22 May 2025
View Exhibitor Profile

CPHI Frankfurt 2025

Messe, Frankfurt
28 Oct 2025 - 30 Oct 2025
View Exhibitor Profile

Products from CARBOGEN AMCIS (8)

  • Analytical Services

    Product Analytical Services

    The complete integration of analytical sciences into the process of API development is fundamentally understood at CARBOGEN AMCIS. Our scientists, technique ranges, systems (including a fully validated LIMS) and procedures facilitate a full understanding of the unique characteristics of the complex molecul...
  • Clinical API Development

    Product Clinical API Development

    CARBOGEN AMCIS has a DNA in API development, stretching back over 30 years. Our API development teams are selected for their passion for science and experience in the application of phase-appropriate efforts to solve challenging chemistry issues. From taking a promising molecule from our clients' medicinal...
  • Commercialization Services

    Product Commercialization Services

    CARBOGEN AMCIS has a track record, extending over 25 years, helping our customers transition their molecules from process development through validation and ultimately into commercial status. A range of services backed up with fully integrated support functions has been developed to facilitate and smooth t...
  • Drug Products

    Product Drug Products

    CARBOGEN AMCIS has developed a comprehensive range of services for the formulation of New Molecular Entities (NMEs) and the reformulation of existing drugs. With a specialization in developing sterile and pyrogen-free parenteral formulations for preclinical and clinical trials (phases I, II and III), CARBO...
  • Highly Potent API

    Product Highly Potent API

    CARBOGEN AMCIS has state of the art facilities and controls to handle both drug substance and drug product of the highest potency and toxicity, under cGMP. Our dedicated containment facilities use a containment methodology, utilizing barrier isolation technology and Rapid Transfer Ports (RTPs), combined wi...
  • Sterile Drug Product services

    Product Sterile Drug Product services

    CARBOGEN AMCIS offers Sterile Drug Product services, specializing in the formulation, development, and manufacturing of injectable products. With capabilities in lyophilization, sterile filling, and handling highly potent APIs, the company ensures aseptic processing for clinical and commercial supply. ...
  • Drug Substance Services

    Product Drug Substance Services

    CARBOGEN AMCIS provides comprehensive Drug Substance services, offering expertise in process development, scale-up, and manufacturing of active pharmaceutical ingredients (APIs). With state-of-the-art facilities, the company specializes in high-potency compounds, including cytotoxics, and delivers solu...
  • Specialties Services and Products

    Product Specialties Services and Products


    Specialty manufacturing and services provided by CDMOs address the diverse needs of customers in various therapeutic, nutraceutical and dietary supplement areas, as well as in the pharma, personal care, and cosmetics industries.

    With over 70 years of experience, CARBOGEN AMCIS Ve...

CARBOGEN AMCIS Resources (4)

  • News CARBOGEN AMCIS acquires new property at Bubendorf site

    BUBENDORF, Switzerland (24 June, 2021) Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced the acquisition of a new property in Bubendorf.
    11 Aug 2021
  • Company Profile

    Brochure Company Profile

    Dowload our brochure and learn more about our offers. 
    Drug development to Commercialization services for pharmaceutical and biopharmaceutical industries at all stages of drug development

    Your CDMO from Drug Substance to Drug Product

  • News Dishman Carbogen Amcis Ltd announces successful results from the partnership with Boston University School of Medicine

    Ahmedabad, India (May 21th, 2021) — India-based Dishman Carbogen Amcis Limited, a global outsourcing partner for the pharmaceutical industry, welcomes the results of a new study that provides critical insights into the treatment of vitamin D deficiency in obesity and in fat malabsorption syndromes. The research was conducted by Boston University School of Medicine and supported in part by a grant from Dishman Carbogen Amcis Ltd’s wholly owned subsidiary CARBOGEN AMCIS B.V.
    11 Aug 2021
  • CARBOGEN AMCIS announces major investments of more than CHF 100 million in Switzerland and France

    News CARBOGEN AMCIS announces major investments of more than CHF 100 million in Switzerland and France

    Switzerland-based CARBOGEN AMCIS, a pharmaceutical process development and Active Pharmaceutical Ingredient (API) and drug products manufacturing company, announced today new expansion plans in Switzerland and France.
    3 Sep 2020